The study, titled "2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide," has been published in the prestigious Journal of Medicinal Chemistry.
Led by Dr. Wun-Teng Wong, Manager of Preclinical/Clinical Transition of Drug Development, the research team successfully developed the long-acting GLP-1 receptor agonist TE-8105, which demonstrates superior efficacy compared to Semaglutide. This breakthrough offers new hope for the treatment of metabolic disorders!
Link to article:
https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02153
News website link:
https://news.gbimonthly.com/tw/article/show.php?num=75284&range=news